Malignant mesothelioma 2008

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 4, 2008, Pages 303-309

  Zervos, Michael D ^a   Bizekis, Costas ^a   Pass, Harvey I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mesothelin; Mesothelioma; Osteopontin; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; INTERLEUKIN 2; MESOTHELIN; OSTEOPONTIN; PACLITAXEL; PEMETREXED; RALITREXED;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; HYPERTHERMIC THERAPY; IMAGING; IMMUNOMODULATION; LABORATORY TEST; LUNG RESECTION; MALIGNANT MESOTHELIOMA; PHOTODYNAMIC THERAPY; PLEURECTOMY; PROGNOSIS; RADIATION DOSE; REVIEW; SIMIAN VIRUS 40; SOLITARY FIBROUS TUMOR; THORACOSCOPY; TREATMENT RESPONSE; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 44649195204     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328302851d     Document Type: Review

References (68)

1. Cheng JQ, Jhanwar SC, Klein WM, et al. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54:5547-5551.
2. Yang CT, You L, Lin YC, et al. A comparison analysis of antitumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 2003; 23:33-38.
3. Yang CT, You L, Uematsu K, et al. P14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61:5959-5963.
4. Marsella JM, Liu BL, Vaslet CA, et al. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 1997; 105 (Suppl 5):1069-1072.
5. Amin KM, Litzky LA, Smythe WR, et al. Wilm's tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146:344-356.
6. Cheng JQ, Lee WC, Klein MA, et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999; 24:238-242.
7. Silver BJ. Platelet-derived growth factor in human malignancy. Biofactors 1992; 3:217-227.
8. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80:892-897.
9. Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat Rev Cancer 2002; 2:957-964.
10. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993; 142:1524-1533.
11. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A 2006; 103:14128-14133.
12. Usami N, Iwano S, Yokoi K. Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography. J Thorac Oncol 2007; 2:1124-1125.
13. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564-1573.
14. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16:259-268.
15. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARKTM: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53:666-672.
16. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-272.
17. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354:496-507.
18. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003; 126:11-16.
19. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005; 129:1364-1370.
20. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46:983-995.
21. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006; 132:763-768.
22. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005; 49 (Suppl 1):S37-S40.
23. Carbone M, Abelda S, Broaddus VC, et al. Eighth international interest group. Oncogene 2007; 26:6959-6967.
24. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007; 110:2248-2252.
25. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998; 12:972-981.
26. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-731.
27. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55:731-735.
28. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2:957-965.
29. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004; 10:849-859.
30. Butchart EG. Contemporary management of malignant pleural mesothelioma. Oncologist 1999; 4:488-500.
31. American Joint Committee on Cancer. AJCC Cancer Staging, 6th ed. Philadelphia, PA: Springer; 2002. p. 2005.
32. Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest 2001; 119:1641-1646.
33. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest 2007; 131:1232-1234.
34. Waite K, Gilligan D. The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol) 2007; 19:182-187.
35. Pilling JE, Stewart DJ, Martin-Ucar AE, et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004; 25:497-501.
36. Edwards JG, Stewart DJ, Martin-Ucar A. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg 2006; 131:981-987.
37. Bean SM, Eloubeidi MA, Cerfolio R, et al. Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma. Diag Cytopathol 2008; 36:32-37.
38. Nakas A, Martin-Ucar AE, Edwards JG, Waller DA. Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery. Eur J Cardiothorac Surg 2008; 33:303-306.
39. Treasure T, Tan C, Lang-Lazdunski L, Waller D. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006; 5:58-59.
40. Nakas A, Martin-Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33:83-88.
41. Edwards JG, Martin-Ucar AE, Stewart DJ, Waller DA. Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy. Short- and long-term results. Eur J Cardiothorac Surg 2007; 31:759-764.
42. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128:138-146.
43. Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008; 85:257-264.
44. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122:788-795.
45. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997; 4:215-222.
46. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68:1799-1804.
47. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54-63.
48. Holsti LR, Pyrhonen S, Kajanti M, et al. Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol 1997; 36:397-405.
49. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-535.
50. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7:1157-1168.
51. Linden CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J 1996; 9:2565-2572.
52. Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and nonsmall-cell lung cancer. J Clin Oncol 1998; 16:635-641.
53. Chen Y, Pandya K, Keng PP, et al. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 2001; 24:432-437.
54. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005; 63:1045-1052.
55. Stevens CW, Forster KM, Smythe WR, Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19:1099-1115.
56. Chan MF, Chui CS, Song Y, et al. A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons. Radiother Oncol 2006; 79:218-223.
57. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84:1685-1693.
58. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004; 5:290-298.
59. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12:1156-1163.
60. Rusch VW, Niedzwiecki D, Tao Y, et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992; 10:1001-1006.
61. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology 2002; 16:907-913.
62. Weder W, Stahel RA, Bernhard J, et al. Swiss Group for Clinical Cancer Research. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18:1196-1202. Demonstrates that multimodality therapy offers improved survival.
63. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006; 1:289-295.
64. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 4:628-633.
65. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24:1561-1567.
66. Lucchi M, Chella A, Melfi F, et al. A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007; 31:529-534.
67. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (poststudy) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16:923-927.
68. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889.